19 unchanged sentences
From time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K).
−Removed: During the three months ended December 31, 2024, our officers and directors took the following actions with respect to 10b5-1 trading arrangements:
−Removed: On October 9, 2024 , Fang Ni , Pharm.D., our former Chief Business Officer and Chief Financial Officer , terminated a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Ni 10b5-1 Plan).
−Removed: The Ni 10b5-1 Plan was adopted on June 29, 2024, had a term of one year and provided for the sale of up to 40,470 shares of common stock pursuant to its terms.
−Removed: No shares have been sold under the Ni 10b5-1 Plan as of the date of its termination.
+Added: During the three months ended December 31, 2025, none of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this Annual Report on Form 10-K.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
23 unchanged sentences
001-39200) filed on June 6, 2024)
−Removed: Second Amended and Restated By-laws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant ’ s Annual Repo rt on Form 10- K (Fi le No.
+Added: Second Amended and Restated By-laws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant’s Annual Report on Form 10-K (File No.
001-39200) filed on March 12, 2024)
31 unchanged sentences
001-39200) filed on September 18, 2023)
−Removed: 10.13# Separation Agreement between the Registrant and Fang Ni, dated as of October 7, 2024 (incorporated by reference to Exhibit 10.12 of the Registrant’s Quarterly Report on Form 10-Q (File No.
−Removed: 001-39200) filed on November 5, 2024)
10.13#+ Amended and Restated Non-Employee Director Compensation Plan, effective February 14, 2024 (incorporated by reference to Exhibit 10.15 of the Registrant’s Annual Report on Form 10-K (File No.
3 unchanged sentences
001-39200) filed on August 11, 2020)
+Added: 10.15+† License Agreement, dated as of March 18, 2025, by and between Servier Pharmaceuticals LLC and the Registrant (incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q (File No.
+Added: 001-39200) filed on May 12, 2025)
19 Black Diamond Therapeutics, Inc.
−Removed: Insider Trading Policy
+Added: Insider Trading Policy (incorporated by reference to Exhibit 19 of the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-39200) filed on March 6, 2025)
21.1 Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of the Registrant’s Annual Report on Form 10-K (File No.
21 unchanged sentences
Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent specifically incorporated by reference into such filing.
+Added: † Portions of this exhibit (indicated by asterisks) were omitted in accordance with the rules of the Securities and Exchange Commission.
Form 10-K Summary
25 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.